Financial Performance - The company's operating revenue for 2023 reached ¥717,929,698.22, an increase of 18.20% compared to ¥607,374,425.39 in the previous year[3] - Net profit attributable to shareholders was ¥99,839,917.15, reflecting a growth of 22.49% from ¥81,509,632.97 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥81,541,176.55, which is a significant increase of 66.10% compared to ¥49,091,074.90 in the previous year[3] Assets and Equity - Total assets at the end of the reporting period amounted to ¥1,802,857,753.87, representing a year-on-year growth of 29.22%[5] - Shareholders' equity attributable to the company increased to ¥1,487,751,566.87, a rise of 35.92% from ¥1,094,590,207.74[3] Share Capital and Earnings - The company's share capital increased by 33.27% to 122,577,200 shares due to the issuance of 30.6 million shares following its listing on the Beijing Stock Exchange[6] - Basic earnings per share decreased by 3.37% to ¥0.86 from ¥0.89 in the previous year[3] - The weighted average return on equity (ROE) before deducting non-recurring gains and losses was 6.76%, down from 7.67%[3] Government Subsidies and Caution - The company recognized government subsidies related to assets amounting to ¥17,373,600 as regular income in 2023, contributing to the increase in net profit[6] - The company advises investors to be cautious as the financial data presented is preliminary and has not been audited, with potential discrepancies expected in the final annual report[8]
星昊医药(430017) - 2023 Q4 - 年度业绩